NGK LAW PROVIDES ZOFRAN LAWSUIT NEWS UPDATE: Lawyers Examine Zofran Birth Defect Studies
St. Louis, MO (PRWEB) March 22, 2015 -- Zofran attorneys at NGK Law have created a new website devoted to allegations in a recent lawsuit regarding potential links between the use of Zofran for morning sickness during pregnancy and the risk of Zofran birth defects. The studies have been cited in a recent Zofran lawsuit, which was recently filed in U.S. District Court in Massachusetts which alleges that Zofran exposure caused congenital birth defects in the plaintiff’s child, including Zofran heart defects and other various birth defects.
The Massachusetts Zofran lawsuit, which is captioned LeClair v. GlaxoSmithKline LLC, Case No. 1:15-CV-10429, filed 2/16/15, cites to several studies which found a heightened risk of birth defects for pregnant women taking Zofran while pregnant. The lawsuit alleges that as early as 1992, GlaxoSmithKline began receiving reports of birth defects, such as Zofran heart birth defects, associated with the use of Zofran by pregnant women for morning sickness. The lawsuit states that by 2000, GlaxoSmithKline had received at least 32 reports of birth defects arising from the use of Zofran for morning sickness in pregnant women. These 32 reports of birth defects included Zofran birth defects such as congenital heart disease, stillbirth, kidney malformation, congenital diaphragmatic anomaly, muscular skeletal anomalies, and other Zofran birth defects such as orofacial anomalies. The Zofran lawsuit states that the most commonly reported birth defects arising from Zofran use during pregnancy were congenital heart defects.
The LeClair v. GlaxoSmithKline LLC Zofran lawsuit also cites to three recent epidemiological studies that have examined the association between exposure to Zofran during pregnancy and the risk of Zofran heart defects in babies. These studies included the Pasternak study, the Andersen study, and the Danielsson study. The lawsuit alleges that in the Pasternak study, it was found that women taking Zofran during the first trimester, compared to women who did not take Zofran, were 22% more likely to have offspring with a septal defect, 41% more likely to have offspring with a ventricular septal defect, and greater than four times more likely to have offspring with atrial ventricular septal defect. The Andersen study, according to the lawsuit, found that there was a higher likelihood for women that took Zofran for morning sickness of having children with a congenital heart defect, and also a 2-4 fold greater risk of having a baby with a Zofran cardiac defect. Finally, the lawsuit cites to the Danielsson study, which found a 62% increased risk of a Zofran heart defect and a greater than 2 fold increased risk of a Zofran septal cardiac defect.
Pasternak B, Svanstrom, H, Hviid, A Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes, N Engl J Med 2013; 368: 814-823.
Andersen, et al. Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations-A Register Based Nationwide Control Study. Presented at International Society of Pharmaco-epidemiology, Montreal, Canada (2013)
Danielsson, et al. Ondansetron During Pregnancy and Congenital Malformations in the Infant (Oct. 31, 2014).
Mark Niemeyer, a partner with NGK Law, had the following to say after reviewing the Zofran lawsuit and relating studies. “It is known the first trimester of pregnancy see some of the most important development of a fetus. The introduction of potentially hazardous chemicals and medications to a pregnancy only increases risks of potential birth defects on children.” The national pharmaceutical lawyers at NGK Law are committed to investigating the potential for Zofran birth defects and the risks that Zofran may pose during pregnancy.
NGK Law is evaluating cases for children and their families that have suffered from birth defects, including heart defects, club foot, facial defects, cleft palate, and other birth defects after mothers took Zofran during the first trimester of pregnancy. With NGK Law’s extensive experience in handling other pharmaceutical birth defect lawsuits for its clients, NGK Law is well equipped to both investigate and handle your Zofran birth defect lawsuit. NGK Law’s partners are available to speak with clients directly regarding their unfortunate birth defects and whether or not they have grounds for a Zofran birth defect lawsuit. Those that have children with birth defects after they took Zofran during pregnancy can contact NGK Law and its Zofran attorneys through its website http://www.zofranbirthdefectlawcenter.com. NGK Law also welcomes the chance to work with other attorneys on Zofran lawsuits.
About Niemeyer, Grebel & Kruse, LLC
Niemeyer, Grebel & Kruse, LLC is a St. Louis based mass tort and personal injury law firm handling pharmaceutical and medical device injury and death cases around the United States. Its track record of assisting those injured by dangerous drugs and medical devices shows its unending commitment to its clients and to holding pharmaceutical drug manufacturers and medical device manufacturers accountable for their dangerous products. Given its experience and accomplishment in being recognized by federal courts to lead litigation on behalf of thousands of individuals, NGK Law is considered a nationwide leader in pharmaceutical and drug litigation. The NGK Law Firm Zofran lawyers provide information to the public at http://www.zofranbirthdefectlawcenter.com.
David Grebel, NGK Law Firm, http://ngklawfirm.com/, +1 314-241-1919, [email protected]
Share this article